Life science investment firm Ally Bridge Group (ABG) has led three US medtech investments amid the Covid-19 pandemic.
Each of the three companies could have a role to play as the pandemic continues.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ABG has led a $25m investment in Vida Health, an all-in-one virtual care platform managing polychronic physical and behavioural conditions such as diabetes, obesity, hypertension and mental health conditions.
The investment group has also led a $60m investment in Rapid Micro Biosystems, a life science tools company that offers products for the detection and data-tracking of bacterial contamination in the manufacturing of pharmaceuticals, biologics, medical devices, water and food processing, and personal care products.
Finally, it has led an investment of a further $66m in Pulmonx, a medical device company specialising in minimally invasive treatment for patients with severe emphysema.
ABG founder and CEO Frank Yu said: “The Covid-19 pandemic is undoubtedly a watershed event for life science and healthcare around the globe, and further strengthens ABG’s commitment to leading high-impact investments in game-changing innovations in this space.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
